Literature DB >> 18211287

Induction of ID1 expression and apoptosis by the histone deacetylase inhibitor (trichostatin A) in human acute myeloid leukaemic cells.

W-P Yu1, S A Scott, W-F Dong.   

Abstract

INTRODUCTION: ID1, founding member of the inhibitor of differentiation (ID) family, is involved in cell population growth, apoptosis and tumourigenesis. METHODS AND
RESULTS: We investigated mRNA levels of ID1 in human myeloid leukaemic cell lines and in specimens of patients with acute myeloid leukaemia (AML), using semiquantitative reverse transcription-polymerase chain reaction, and protein levels of ID1 in human myeloid leukaemic cell lines using Western blot analysis. Six of seven AML cell lines and 12 of 15 AML patient samples were found to have barely detectable ID1 mRNA. All of these cell lines showed the same levels of protein in proportion to levels of mRNA. Two of the AML cell lines with low ID1 expression, KG1 and KG-1a, were chosen for treatment with either the DNA demethylation reagent, 5-aza-2'-deoxycytidine (DAC), or the histone deacetylase (HDAC) inhibitor, trichostatin A (TSA). These treatments were alone or in combination, and ID1 expression was induced by both DAC and TSA. No hypermethylated ID1 gene promoter was detected in the majority of the cell lines and patient specimens, by methylation-specific polymerase chain reaction, suggesting that induction of ID1 in KG1 and KG-1a was not due to direct demethylation of the ID1 gene promoter. Chromatin immunoprecipitation showed that accumulation of acetyl-histone H3 and release of HDAC1 were correlated with ID1 induction by these drugs. Flow cytometric assay demonstrated more apoptosis induced by TSA or TSA in combination with DAC, in both KG-1 and KG-1a cell lines. Increase of intracellular reactive oxygen species was observed when treated with TSA.
CONCLUSION: Most AML cell lines and human AML samples have very low levels of expression of ID1. TSA or TSA in combination with DAC is able to restore ID1 expression in low ID1-expressing AML cell lines by re-activating the aberrantly deacetylated promoter, and this also results in more apoptotic cell death, in which ID1 and the redox pathway may be involved.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18211287      PMCID: PMC6496488          DOI: 10.1111/j.1365-2184.2007.00499.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  30 in total

1.  Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex.

Authors:  Jarnail Singh; Kenji Murata; Yoko Itahana; Pierre-Yves Desprez
Journal:  Oncogene       Date:  2002-03-14       Impact factor: 9.867

2.  Expression of Id helix-loop-helix proteins in colorectal adenocarcinoma correlates with p53 expression and mitotic index.

Authors:  J W Wilson; R W Deed; T Inoue; M Balzi; A Becciolini; P Faraoni; C S Potten; J D Norton
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

3.  Expression of Id1 results in apoptosis of cardiac myocytes through a redox-dependent mechanism.

Authors:  K Tanaka; J B Pracyk; K Takeda; Z X Yu; V J Ferrans; S S Deshpande; M Ozaki; P M Hwang; C J Lowenstein; K Irani; T Finkel
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

4.  Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins.

Authors:  Kevin A Strait; Bashar Dabbas; Elizabeth H Hammond; C Terry Warnick; Sarah J Iistrup; Clyde D Ford
Journal:  Mol Cancer Ther       Date:  2002-11       Impact factor: 6.261

5.  Trichostatin A modulates expression of p21waf1/cip1, Bcl-xL, ID1, ID2, ID3, CRAB2, GATA-2, hsp86 and TFIID/TAFII31 mRNA in human lung adenocarcinoma cells.

Authors:  B Eickhoff; S Rüller; T Laue; G Köhler; C Stahl; M Schlaak; J van der Bosch
Journal:  Biol Chem       Date:  2000-02       Impact factor: 3.915

6.  5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.

Authors:  Stuart A Scott; Wei-Feng Dong; Ryo Ichinohasama; Calley Hirsch; David Sheridan; Stephen E Sanche; C Ronald Geyer; John F Decoteau
Journal:  Leuk Res       Date:  2005-07-25       Impact factor: 3.156

7.  Over expression of ID-1 in prostate cancer.

Authors:  X S Ouyang; X Wang; D T W Lee; S W Tsao; Y C Wong
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

8.  Expression and significances of Id1 helix-loop-helix protein overexpression in gastric cancer.

Authors:  Shuang Han; Changcun Gou; Liu Hong; Jie Liu; Changjiang Liu; Jin Wang; KaiChun Wu; Jie Ding; Daiming Fan
Journal:  Cancer Lett       Date:  2004-12-08       Impact factor: 8.679

9.  Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors.

Authors:  Monika Schindl; Sebastian F Schoppmann; Thomas Ströbel; Harald Heinzl; Christina Leisser; Reinhard Horvat; Peter Birner
Journal:  Clin Cancer Res       Date:  2003-02       Impact factor: 12.531

10.  Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma.

Authors:  O Straume; L A Akslen
Journal:  Br J Cancer       Date:  2005-10-17       Impact factor: 7.640

View more
  8 in total

1.  Clinical significance of up-regulated ID1 expression in Chinese de novo acute myeloid leukemia.

Authors:  Jing-Dong Zhou; Lei Yang; Xiao-Wen Zhu; Xiang-Mei Wen; Jing Yang; Hong Guo; Qin Chen; Dong-Ming Yao; Ji-Chun Ma; Jiang Lin; Jun Qian
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

2.  Regulation of AURKC expression by CpG island methylation in human cancer cells.

Authors:  Satoshi Fujii; Vibhuti Srivastava; Apurva Hegde; Yutaka Kondo; Lanlan Shen; Koyu Hoshino; Yvette Gonzalez; Jin Wang; Kaori Sasai; Xiaotu Ma; Hiroshi Katayama; Marcos R Estecio; Stanley R Hamilton; Ignacio Wistuba; Jean-Pierre J Issa; Subrata Sen
Journal:  Tumour Biol       Date:  2015-05-20

3.  Basic helix loop helix (bHLH) transcription factor 3 (TCF3, E2A) is regulated by androgens in prostate cancer cells.

Authors:  Divya Patel; Swathi Chinaranagari; Jaideep Chaudhary
Journal:  Am J Cancer Res       Date:  2015-10-15       Impact factor: 6.166

Review 4.  Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy.

Authors:  Leila Haery; Ryan C Thompson; Thomas D Gilmore
Journal:  Genes Cancer       Date:  2015-05

Review 5.  The emerging role of Twist proteins in hematopoietic cells and hematological malignancies.

Authors:  N Merindol; A Riquet; V Szablewski; J-F Eliaou; A Puisieux; N Bonnefoy
Journal:  Blood Cancer J       Date:  2014-04-25       Impact factor: 11.037

6.  DNA methylation profiling across the spectrum of HPV-associated anal squamous neoplasia.

Authors:  Jonathan M Hernandez; Erin M Siegel; Bridget Riggs; Steven Eschrich; Abul Elahi; Xiaotao Qu; Abidemi Ajidahun; Anders Berglund; Domenico Coppola; William M Grady; Anna R Giuliano; David Shibata
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

7.  Down-regulation of sirtuin 3 is associated with poor prognosis in hepatocellular carcinoma after resection.

Authors:  Jia-Xing Wang; Yong Yi; Yi-Wei Li; Xiao-Yan Cai; Hong-Wei He; Xiao-Chun Ni; Jian Zhou; Yun-Feng Cheng; Jian-Jun Jin; Jia Fan; Shuang-Jian Qiu
Journal:  BMC Cancer       Date:  2014-04-28       Impact factor: 4.430

Review 8.  Inhibitor of Differentiation 1 (Id1) in Cancer and Cancer Therapy.

Authors:  Zhengxiao Zhao; Zhiyuan Bo; Weiyi Gong; Yong Guo
Journal:  Int J Med Sci       Date:  2020-04-06       Impact factor: 3.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.